Reply to: Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C

Cecilia T Costiniuk^{1

2

3

4}, Mohammad-Ali Jenabian^{4

5

6}

Affiliations

¹ Chronic Viral Illness Service and Division of Infectious Diseases, Department of Medicine.
² Infectious Diseases and Immunity in Global Health Program, Research Institute of McGill University Health Centre.
³ McGill Research Centre for Cannabis and The Mark Wainberg Centre for Viral Diseases.
⁴ Department of Microbiology and Immunology, McGill University.
⁵ Department of Biological Sciences, University of Quebec at Montreal (UQAM).
⁶ Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Comment

Cecilia T Costiniuk et al. AIDS. 2020.

. 2020 May 1;34(6):955-956.

doi: 10.1097/QAD.0000000000002481.

Cecilia T Costiniuk^{1

2

3

4}, Mohammad-Ali Jenabian^{4

5

6}

¹ Chronic Viral Illness Service and Division of Infectious Diseases, Department of Medicine.
² Infectious Diseases and Immunity in Global Health Program, Research Institute of McGill University Health Centre.
³ McGill Research Centre for Cannabis and The Mark Wainberg Centre for Viral Diseases.
⁴ Department of Microbiology and Immunology, McGill University.
⁵ Department of Biological Sciences, University of Quebec at Montreal (UQAM).
⁶ Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

No abstract available

Comment on

Cannabinoids and inflammation: implications for people living with HIV.
Costiniuk CT, Jenabian MA. Costiniuk CT, et al. AIDS. 2019 Dec 1;33(15):2273-2288. doi: 10.1097/QAD.0000000000002345. AIDS. 2019. PMID: 31764093 Review.
Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection.
Santos ME, Protopopescu C, Zucman D, Marcellin F, Wittkop L, Miailhes P, Sogni P, Carrieri MP. Santos ME, et al. AIDS. 2020 May 1;34(6):953-954. doi: 10.1097/QAD.0000000000002480. AIDS. 2020. PMID: 32271254 No abstract available.

1. Santos ME, Protopopescu C, Zucman D, Marcellin F, Wittkop L, Miailhes P, et al. Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. AIDS 2020; 34:953–954.
1. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42:63–71.
1. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134:432–439.
1. Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008; 6:69–75.
1. Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis 2013; 57:663–670.